Spyre Therapeutics Inc expected to post a loss of $1.17 a share - Earnings Preview

Spyre Therapeutics

07/05/2024 18:01

* Spyre Therapeutics Inc  SYRE.OQ   SYRE.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 9
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Spyre Therapeutics Inc
is for
a loss of $1.17 per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 1.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Spyre
Therapeutics Inc is $50.00​, above​ its last closing price
of $35.77. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.52       -0.78      -4.05     Missed  -416.4
 Jan. 1 0001   -0.68       -0.84      -9.34     Missed  
 Jun. 30 2023  -4.50       -4.50      -41.50    Missed  -822.2
                                                        ​
 Mar. 31 2023  -4.75       -4.50      -5.00     Missed  -11.1
 ​​Sep.        -5.04       -5.00      -4.50     Beat    10
 30 2022                                                
 Jan. 1 0001   -5.79       -5.80      -4.75     Beat    18.1​
 Jan. 1 0001   -7.71       -7.79      -6.75     Beat    13.4
 Mar. 31 2022  -8.32                  -9.25             -9.9
 This summary was machine generated May 7 at 17:01 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)